// App-Quantinova.ai

4018 : Hyper-CVAD Plus Epratuzumab As Salvage Regimen for Younger Relapsed/Refractory CD22+ B Acute Lymphoblastic Leukemia (ALL) Patients: Results of the Phase 2 Prospective Cheprall Study

Researchers

Presenter

  • Patrice Chevallier

Principal Investigators

  • Francoise Huguet

  • Nelly Robillard

  • Thierry Guillaume

  • Pierre Peterlin

  • Alice Garnier

  • Fanny Rialland

  • Claire Le Houerou

  • David M Goldenberg

  • William Wegener

  • Marie C Bene

  • Herve Dombret

  • Emmanuel Raffoux

  • Xavier Thomas

  • Thibaut Leguay

  • Tony Marchand

  • Francoise Isnard

  • Aude Charbonnier

  • Sebastien Maury

  • Maria-Pilar Gallego-Hernanz

Medical Centers

  • France

  • AP-HP, Hematologie Clinique et Therapie Cellulaire, Hopital Saint-Antoine, Paris, France,

  • Hematology department, Institut Paoli-Calmette, Marseilles,

  • Hospital Saint Antoine, Paris, France

  • Department of Hematology, Centre Hospitalier Universitaire Caen, Caen, France

  • Department of Biochemistry, Nantes University Hospital, Nantes, France

  • CHU, Lyon, France

  • Pediatric Department, Nantes university hospital, Nantes, France

  • Institut d'Hematologie de Basse Normandie, Caen, France

  • Biochemistry Laboratory, Nantes University Hospital, Nantes, France

  • Pathology, CHU Bordeeaux, Pessac, France

  • Dermatology Department, Saint Louis Hospital, Paris, France

  • Hematology Department, CHU, Angers, France

  • Dermatology department, Institut Universitaire du Cancer de Toulouse et CHU de Toulouse, Toulouse, France

  • Hematology Department, CHU, Angers, France

  • Department of Hematology, Centre Hospitalier Universitaire Caen, Caen, France

Locations

  • France

Companies

  • Immunomedics, Inc.

Study Components

Therapeutic Area

  • Genetic Disorder

  • Central Nervous System (CNS)

Disease

  • Acute lymphoblastic leukemia

  • Intracerebral hemorrhage

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Epratuzumab

  • Vincristine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved